Clinical trial
A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety…
NCT00369161 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00369161 |
|---|---|
| Title | A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients |
| Official title | A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With IL-2 Receptor Antagonist, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Renal Transplantation |
| Intervention type | Drug |
| Interventions | Everolimus (RAD001), Tacrolimus, Basiliximab, Corticosteroids |
| Enrollment | 228 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Aug 29, 2006 |
| Last update posted | Mar 3, 2017 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: